Aptinyx - APTX Stock Forecast, Price & News

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on APTX shares. SVB Leerink cut their price objective on shares of Aptinyx from $4.00 to $3.00 and set an "outperform" rating on the stock in a report on Friday. HC Wainwright reduced their price target on Aptinyx from $8.00 to $2.00 and set a "buy" rating for the company in a report on Thursday, April 14th. Finally, Piper Sandler lowered their price target on Aptinyx from $10.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, May 18th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $4.50.

Aptinyx Stock Performance

Shares of NASDAQ:APTX traded up $0.02 during trading hours on Friday, hitting $0.51. The stock had a trading volume of 242,733 shares, compared to its average volume of 149,757. Aptinyx has a 1-year low of $0.36 and a 1-year high of $3.76. The company has a debt-to-equity ratio of 0.31, a quick ratio of 22.49 and a current ratio of 22.49. The firm has a market capitalization of $34.86 million, a price-to-earnings ratio of -0.45 and a beta of 1.24. The stock's fifty day simple moving average is $0.53 and its 200 day simple moving average is $1.59.

Aptinyx (NASDAQ:APTX - Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02. During the same quarter last year, the business posted ($0.22) earnings per share. Sell-side analysts anticipate that Aptinyx will post -0.99 earnings per share for the current fiscal year.